{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T12:35:23Z","timestamp":1772714123477,"version":"3.50.1"},"reference-count":32,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2012,11,5]],"date-time":"2012-11-05T00:00:00Z","timestamp":1352073600000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Wound Repair Regeneration"],"published-print":{"date-parts":[[2012,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The rising costs of caring for chronic cutaneous ulcers (<jats:styled-content style=\"fixed-case\">CCU<\/jats:styled-content>s) and recent appreciation of the mortality of <jats:styled-content style=\"fixed-case\">CCU<\/jats:styled-content>s have led to consideration of the reasons for the failure to have new drug therapies. No new chemical entities to heal <jats:styled-content style=\"fixed-case\">CCU<\/jats:styled-content>s have been approved by the Food and Drug Administration (<jats:styled-content style=\"fixed-case\">FDA<\/jats:styled-content>) in over a decade, in part due to an inability to reach the <jats:styled-content style=\"fixed-case\">FDA<\/jats:styled-content> accepted end point of \u201ccomplete wound closure.\u201d The frequent failure to reach the complete closure end point brings forward the question of the relevance of other healing end points such as improved quality of life, or partial healing. Because <jats:styled-content style=\"fixed-case\">CCU<\/jats:styled-content>s carry a prognosis and mortality rate worse than many cancers, it is reasonable to compare the <jats:styled-content style=\"fixed-case\">FDA<\/jats:styled-content> trial end points for cancer drug approval with those for <jats:styled-content style=\"fixed-case\">CCU<\/jats:styled-content>s. And the difference is quite striking. While there is only one end point for <jats:styled-content style=\"fixed-case\">CCU<\/jats:styled-content>s, there are five surrogate and three direct end points for cancers. In contrast to cancer, surrogate end points and partial healing are not acceptable for therapies aimed at <jats:styled-content style=\"fixed-case\">CCU<\/jats:styled-content>s. For example, making tumors smaller is an acceptable end point, but making <jats:styled-content style=\"fixed-case\">CCU<\/jats:styled-content>s smaller is not and improvement in the signs and symptoms of cancer is an acceptable end point for cancers but not <jats:styled-content style=\"fixed-case\">CCU<\/jats:styled-content>s. As <jats:styled-content style=\"fixed-case\">CCU<\/jats:styled-content>s carry a prognosis and mortality rate worse than many cancers, we believe a reconsideration of end points for <jats:styled-content style=\"fixed-case\">CCU<\/jats:styled-content>s is highly warranted.<\/jats:p>","DOI":"10.1111\/j.1524-475x.2012.00849.x","type":"journal-article","created":{"date-parts":[[2012,11,5]],"date-time":"2012-11-05T18:07:49Z","timestamp":1352138869000},"page":"793-796","source":"Crossref","is-referenced-by-count":40,"title":["Food and Drug Administration (<scp>FDA<\/scp>) drug approval end points for chronic cutaneous ulcer studies"],"prefix":"10.1111","volume":"20","author":[{"given":"William H.","family":"Eaglstein","sequence":"first","affiliation":[{"name":"Department of Dermatology and Cutaneous Surgery University of Miami Miller School of Medicine  Miami Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert S.","family":"Kirsner","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Cutaneous Surgery University of Miami Miller School of Medicine  Miami Florida"},{"name":"Department of Epidemiology and Public Health University of Miami Miller School of Medicine  Miami Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin C.","family":"Robson","sequence":"additional","affiliation":[{"name":"Department of Surgery University of South Florida  Tampa Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,11,5]]},"reference":[{"key":"e_1_2_4_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-475X.2009.00543.x"},{"key":"e_1_2_4_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-481X.2007.00392.x"},{"key":"e_1_2_4_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-481X.2009.00598.x"},{"key":"e_1_2_4_5_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-0651"},{"key":"e_1_2_4_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-475X.2011.00699.x"},{"key":"e_1_2_4_7_1","unstructured":"SalcidoR LorenzoCT.Pressure ulcers and wound care. Medscape Reference [Internet]. Available athttp:\/\/emedicine.medscape.com\/article\/319284(accessed January 6 2012)."},{"key":"e_1_2_4_8_1","first-page":"359","article-title":"Pressure ulcers: etiology and prevention","volume":"22","author":"Maklebust J","year":"1987","journal-title":"Nurs Clin North Am"},{"key":"e_1_2_4_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1976.tb06804.x"},{"key":"e_1_2_4_10_1","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2009.0260"},{"key":"e_1_2_4_11_1","first-page":"45","article-title":"Pressure ulcers in the elderly: prevention and treatment utilizing the team approach","volume":"30","author":"Reed JW","year":"1981","journal-title":"Md State Med J"},{"key":"e_1_2_4_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2011.03262.x"},{"key":"e_1_2_4_13_1","first-page":"28","article-title":"Diabetic foot ulcers\u2013\u2013effects on QOL, costs, and mortality and the role of standard wound care and advanced\u2010care therapies","volume":"55","author":"Snyder RJ","year":"2009","journal-title":"Ostomy Wound Manage"},{"key":"e_1_2_4_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-011-2359-2"},{"key":"e_1_2_4_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198612253152606"},{"key":"e_1_2_4_16_1","first-page":"943","article-title":"Immunosuppression and cancer","volume":"5","author":"Penn I","year":"1973","journal-title":"Transplant Proc"},{"key":"e_1_2_4_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.1592"},{"key":"e_1_2_4_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.313"},{"key":"e_1_2_4_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcibr1106880"},{"key":"e_1_2_4_20_1","unstructured":"KwonP XingB.Topical vascular endothelial growth factor (VEGF telbermin) for neuropathic diabetic foot ulcers: phase II randomized double\u2010blind multi\u2010dose trial. [Internet]. Available athttp:\/\/web.1.c3.audiovideoweb.com\/1c3web3530\/%20dfcon08abstracts\/TopicalVascularEndothelial.pdf(accessed May 16 2011)."},{"key":"e_1_2_4_21_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1524-475x.2001.00347.x"},{"key":"e_1_2_4_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000637-199209000-00001"},{"key":"e_1_2_4_23_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1524-475X.1999.00141.x"},{"key":"e_1_2_4_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-199210000-00002"},{"key":"e_1_2_4_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-200004000-00020"},{"key":"e_1_2_4_26_1","unstructured":"US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) Center for Devices and Radiological Health (CDRH).Guidance for industry chronic cutaneous ulcer and burn wounds\u2013\u2013developing products for treatment.2006. Available athttp:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm071324.pdf(accessed May 16 2011)."},{"key":"e_1_2_4_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9610(00)00536-5"},{"key":"e_1_2_4_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.135.7.773"},{"key":"e_1_2_4_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-4801.2006.00178.x"},{"key":"e_1_2_4_30_1","first-page":"1","article-title":"Wound healing trajectories to determine pressure ulcer treatment","volume":"11","author":"Payne WG","year":"2011","journal-title":"Eplasty"},{"key":"e_1_2_4_31_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2002.19629.x"},{"key":"e_1_2_4_32_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1524-475X.1999.00090.x"},{"key":"e_1_2_4_33_1","unstructured":"US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER).Guidance for industry clinical trial endpoints for the approval of cancer drugs and biologics.2007. Available athttp:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm071590.pdf(accessed May 16 2011)."}],"container-title":["Wound Repair and Regeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1524-475X.2012.00849.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1524-475X.2012.00849.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T07:55:31Z","timestamp":1698652531000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1524-475X.2012.00849.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["10.1111\/j.1524-475X.2012.00849.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1524-475x.2012.00849.x","archive":["Portico"],"relation":{},"ISSN":["1067-1927","1524-475X"],"issn-type":[{"value":"1067-1927","type":"print"},{"value":"1524-475X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}